19 February 2021
Visiongain has published a new report on Hospital Acquired Infection Treatment Market Report 2021-2031: Forecasts By Product Type (Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment, Antiparasitic, Antiprotozoal, Anti TB Treatment, and Others) By Infection Type (Urinary Tract Infection, Ventilator-Associated Pneumonia, Bloodstream Infection, Surgical Site Infection, Gastrointestinal Infection, ENT Infections, Skin Infection, Bone Infection, and Other), By Pathogen Type (Viral, Bacterial, and Fungal), By End User (Hospitals, Homecare, Specialty Clinics, Academic and Research Institute, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Global Hospital Acquired Infection Treatment market was valued at US$ xx Million in 2020 and is projected to reach at a market value of US$ xx Million by 2031. North America dominated the global Hospital Acquired Infection Treatment market and is projected to witness CAGR of XX% during the first half of the forecast period i.e. 2021 to 2031.
COVID-19 Impact on Hospital Acquired Infection Treatment Market
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Hospital Acquired Infection Treatment market. Different recovery scenarios are also included in the report for all the segments and regions/nation. The recovery scenarios based on which market has been forecasted and analysed herein the report are mentioned below:
Increasing Prevalence of Hospital Acquired Infection Treatment
The prevalence of hospital acquired infection disorders and conditions has increased very rapidly across the world and is expected to rise continuously over the forecast period. The increase in the cases of hospital acquired infection disorders creates a huge demand for the hospital acquired infection treatment this gives an opportunity to the manufacturer to come up with innovative and cost effective products to cater the high demand. Due to which increasing prevalence of hospital acquired infection treatment is working as a driver for the hospital acquired infection treatment market.
Increasing Geriatric Population around the World
Geriatric population is increasing very fast around the world from the last few decades. All regions are facing a huge increase in the number of geriatric populations. For instance: According to the United Nations, Department of Economic and Social Affairs, the Population Division geriatric population (persons aged 65 or over) was 702.9 million in 2019. Geriatric populations are at high risk of developing hospital acquired infection due to decreased immune system. Rapid increase in the number of the geriatric population around the globe is also increasing demand for hospital acquired infection treatment around the world. Due to which increasing geriatric population around the world is working as a driver for the hospital acquired infection treatment market.
Increasing focus on Healthcare Infrastructure
Governments from all over the world are Increasing their focus on healthcare infrastructure and advanced healthcare facilities and are taking necessary steps to create or modify healthcare infrastructure. Healthcare infrastructure in developing nations are undergoing alterations from the last few years and each change is only for a better healthcare delivery, and to incorporate all the sections of the population. Increasing focus on healthcare infrastructure is expected to increase public spending which is expected to create new opportunities for the hospital acquired infection treatment market, Moreover, the public private spending will also aid the market growth during the forecast period. Due to this reason the factor is creating various opportunities for drugs of abuse testing market.
Top companies (Abbott Laboratories, Pfizer Inc., and Bayer AG) constitute more than XX% share of the global Hospital Acquired Infection Treatment market. Other companies profiled in the report include: Cepheid, Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Merck & Co., Inc, Cipla Inc., GlaxoSmithKline plc., Aridis Pharmaceuticals, Inc., Astellas Pharma Inc., Daiichi Sankyo, Inc., Bristol-Myers Squibb Company, Eli Lilly and Other Company among) others Some of the key developments are listed below:
● In 2018, Astellas Pharma Inc. launched Dafclir Tablets 200 mg for the treatment of infectious enteritis (including pseudomembranous colitis1). Dafclir is an oral administered macrocyclic antimicrobial agent. The launch had helped the company to its market share in the Hospital Acquired Infection Treatment market.
● In 2017, Pfizer Inc. launched Zavicefta, which is a novel combination antibiotic for the treatment of suspected or confirmed Gram-negative bacterial infections requiring hospitalization. The launch will help the company widen revenue generation from a market focused product portfolio.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032.
21 June 2022
The global nanotechnology in drug delivery market was valued at US$53.0 billion in 2021 and is projected to grow at a CAGR of 18.7% during the forecast period 2022-2032.
20 June 2022
The global respiratory drug delivery technologies market was valued at US$59.51 billion in 2022 and is projected to grow at a CAGR of 7.31% during the forecast period 2022-2032.
15 June 2022
The global artificial intelligence (AI) in drug discovery market was valued at US$791 million in 2021 and is projected to grow at a CAGR of 30.7% during the forecast period 2022-2032.